Skip to main navigation Skip to search Skip to main content

The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany

  • Matthias Augustin
  • , Dominik Beier
  • , Jennifer Branner
  • , Dennis Häckl
  • , Regina Hampel
  • , Thomas Kramps
  • , Hjalmar Kurzen
  • , Hannah Lintener
  • , Nima Melzer
  • , Malina Müller
  • , Petra Staubach
  • , Uwe Schwichtenberg
  • , Christian Termeer
  • , Alexander Zink
  • , Petra Nathan
  • , Marcus Maurer
  • University Medical Center Hamburg-Eppendorf
  • Leibniz-Institut für Katalyse
  • WifOR Institute
  • WIG2 Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung Leipzig
  • GKM Therapieforschung München
  • Novartis Pharma GmbH
  • Haut- und Laserzentrum Freising
  • University Medical Center
  • Derma-Nord Hautarztpraxis Bremen
  • Practice
  • University of Freiburg
  • Technical University of Munich
  • Karolinska Institutet
  • Charité – Universitätsmedizin Berlin
  • Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP)

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Background and Study Aim: Data from the AWARE study (A Worldwide Antihistamine-Refractory chronic urticaria patient Evaluation) illustrate a substantial disease burden in German patients with H1-antihistamine (-H1-AH)-refractory chronic spontaneous urticaria (CSU). Detrimental effects on patients' quality of life, poor disease control and impairment in the ability to work and perform other daily activities are reported. Based on these findings, this study aims to quantify the epidemiological and socio-economic burden of H1-AH-refractory CSU in Germany. Methods: To determine the epidemiological burden of H1-AH-refractory CSU, the age- and gender-specific prevalence of CSU and the proportion of H1-AH-refractory patients in Germany anonymized data from the InGef research database have been used. In a second step, the socio-economic burden in terms of lost numbers of hours in paid and unpaid work was calculated by extrapolating the age- and gender-specific work productivity and activity impairment (WPAI) observed in AWARE to the H1-AH-refractory CSU population in Germany. Finally, productivity losses in paid and unpaid work were monetized using the human capital and the friction cost approach respectively. Moreover, socio-economic burden was calculated depending on symptom control of the patients (measured by urticaria control test [UCT]). Results: In Germany, over 203,000 patients (20 years or older) had H1-AH-refractory CSU in 2018. The avoided lost paid and unpaid work hours attributable to H1-AH-refractory CSU summed up to over 100 million. Overall, the socio-economic burden of H1-AH-refractory CSU in monetary terms was evaluated at € 2.2 billion and the majority of this was due to unpaid work loss. Patients with poor disease control, as indicated by UCT score < 12, were more likely to suffer from high impairment than patients with controlled disease, resulting in a higher socio-economic burden. Conclusions: The results of our analyses picture the substantial socio-economic burden of H1-AH-refractory CSU and therefore the tremendous impact it has on daily lives of individuals and society overall.

Original languageEnglish
Pages (from-to)2102-2109
Number of pages8
JournalJournal of the European Academy of Dermatology and Venereology
Volume38
Issue number11
DOIs
StatePublished - Nov 2024
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany'. Together they form a unique fingerprint.

Cite this